SION
HEALTHCARESionna Therapeutics Inc
What's Moving SION Today?
No stock-specific AI insight has been generated for SION yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$39.87
Fundamentals
Trading
SION News
22 articles- Assessing Sionna Therapeutics (SION) Valuation After A Mixed Period For Recent Share Price ReturnsYahoo Finance·Jun 11, 2026
- Sionna Therapeutics director Peter Thompson sells $4,493 of shares By Investing.comInvesting.com South Africa·May 30, 2026
- OrbiMed Advisors, director, sells $4,493 in Sionna Therapeutics stock By Investing.comInvesting.com Australia·May 30, 2026
- Sionna Therapeutics to Participate in Upcoming June 2026 Investor ConferencesYahoo Finance·May 27, 2026
- Wedbush Initiates Coverage of Sionna Therapeutics (SION)Yahoo Finance·May 14, 2026
- Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare ConferenceYahoo Finance·May 13, 2026
- Sionna Therapeutics Reports First Quarter 2026 Financial ResultsYahoo Finance·May 12, 2026
- A Look At Sionna Therapeutics (SION) Valuation After Its Strong 1 Year Return And Premium P/B RatioYahoo Finance·May 5, 2026
- Sionna Insider Sells $2.5 Million in Stock Amid 215% Surge, but Here's What Investors Should WatchThe Motley Fool·Apr 27, 2026
- Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic FibrosisYahoo Finance·Apr 27, 2026
- Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation SymposiumYahoo Finance·Apr 7, 2026
- Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another StoryThe Motley Fool·Mar 31, 2026
- Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?Motley Fool·Mar 18, 2026
- This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on SharesMotley Fool·Mar 15, 2026
- Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 2, 2026
- Assessing Sionna Therapeutics (SION) Valuation As Premium P/B Meets Cooling Share Price MomentumYahoo Finance·Feb 27, 2026
- Sionna Therapeutics to Participate in Upcoming March 2026 Investor ConferencesYahoo Finance·Feb 23, 2026
- Sionna Therapeutics Maps Mid-2026 CF Catalysts, Highlights NBD1 Stabilizers at Guggenheim SummitMarketbeat·Feb 15, 2026
- Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026Yahoo Finance·Feb 4, 2026
- Sionna Therapeutics Chief Legal Officer Caps Off Strong 2025 with Sale of Over 10,000 SharesMotley Fool·Jan 13, 2026
- Assessing Sionna Therapeutics (SION) Valuation After Recent Share Price Swings And Premium P/B MultipleYahoo Finance·Jan 12, 2026
- Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 5, 2026
All 22 articles loaded
Price Data
52-Week Range
$39.87
Fundamentals
Trading
About Sionna Therapeutics Inc
Sionna Therapeutics, Inc. is a pioneering biotechnology firm dedicated to developing cutting-edge therapies for neurodegenerative disorders, specifically targeting conditions such as Alzheimer's and Parkinson's diseases characterized by protein misfolding. With a strong pipeline bolstered by proprietary technologies, the company is positioned to meet significant unmet medical needs in this critical therapeutic area. Sionna’s strategic collaborations and a steadfast commitment to research and development underscore its status as a key player in the biopharmaceutical landscape, aiming to improve patient outcomes and quality of life through innovative neurological solutions.